Skip to content
Accessibility help
Search NICE…
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
BNF for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In consultation
In consultation: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Deferred
Awaiting development
Topic prioritisation
Filter (4 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Consultation end date
Consultation end date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (12)
Guidance programme
(
3 selected
)
Guidance programme
Clinical guidelines (2)
Medical technologies guidance (0)
Medicines practice guidelines (0)
NICE general (1)
NICE guidelines (2)
NICE process and methods (2)
Technology appraisal guidance (12)
Apply filters
Showing 1 to 10 of 12
Sort by
Date
Title
Apply sorting
Type: Guidance
`Remove $Type: Guidance filter`
Guidance programme: Technology appraisal guidance
`Remove $Guidance programme: Technology appraisal guidance filter`
Guidance programme: Medical technologies guidance
`Remove $Guidance programme: Medical technologies guidance filter`
Guidance programme: Medicines practice guidelines
`Remove $Guidance programme: Medicines practice guidelines filter`
Guidance and quality standards in consultation
Title
Consultation
Type
Consultation end date
Ianalumab for treating active Sjogren's syndrome ID6634
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
4 June 2026
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable [ID6249]
Draft guidance
Technology appraisal guidance
4 June 2026
Nirogacestat for treating desmoid tumours [ID6453]
Draft guidance
Technology appraisal guidance
1 June 2026
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6757]
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
27 May 2026
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]
Draft guidance
Technology appraisal guidance
22 May 2026
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]
Draft guidance
Technology appraisal guidance
21 May 2026
Oveporexton for treating type 1 narcolepsy [ID6622]
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
21 May 2026
Ruxolitinib for treating moderate atopic dermatitis ID6602
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
20 May 2026
Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]
Draft guidance
Technology appraisal guidance
18 May 2026
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]
Final draft guidance
Technology appraisal guidance
14 May 2026
Current page
1
2
Page
1
of
2
Next page
Results per page
10
25
50
All
Back to top